|
1
|
Osimani M, Bellini D, Di Cristofano C,
Palleschi G, Petrozza V, Carbone A and Laghi A: Perfusion MDCT of
prostate cancer: Correlation of perfusion CT parameters and
immunohistochemical markers of angiogenesis. AJR Am J Roentgenol.
199:1042–1048. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Resnick MJ, Koyama T, Fan KH, Albertsen
PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL,
Stroup AM, et al: Long-term functional outcomes after treatment for
localized prostate cancer. N Engl J Med. 368:436–445. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maresca KP, Hillier SM, Femia FJ, Keith D,
Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA,
Eckelman WC, et al: A series of halogenated heterodimeric
inhibitors of prostate specific membrane antigen (PSMA) as
radiolabeled probes for targeting prostate cancer. J Med Chem.
52:347–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mottet N, Bellmunt J, Bolla M, Briers E,
Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau
S, et al: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1:
Screening, Diagnosis, and Local Treatment with Curative Intent. Eur
Urol. 71:618–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen G, Deng H, Hu S and Jia Z: Comparison
of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the
diagnosis of bone metastases in patients with prostate cancer: A
meta-analysis. Skeletal Radiol. 43:1503–1513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stephenson SK, Chang EK and Marks LS:
Screening and detection advances in magnetic resonance image-guided
prostate biopsy. Urol Clin North Am. 41:315–326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Afshar-Oromieh A, Haberkorn U, Schlemmer
HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A
and Röthke M: Comparison of PET/CT and PET/MRI hybrid systems using
a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate
cancer: Initial experience. Eur J Nucl Med Mol Imaging. 41:887–897.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan R, Yao SZ, Huang ZQ, Li J, Li X, Tan
HH and Liu QW: Combination of FDG PET/CT and contrast-enhanced MSCT
in detecting lymph node metastasis of esophageal cancer. Asian Pac
J Cancer Prev. 15:7719–7724. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tobisu K: Clinical and pathological
staging of prostate cancer. Nihon Rinsho. 63:225–230. 2005.(In
Japanese). PubMed/NCBI
|
|
11
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Gao X, Deeb D, Zhang Y, Shaw J,
Valeriote FA and Gautam SC: Mycotoxin verrucarin A inhibits
proliferation and induces apoptosis in prostate cancer cells by
inhibiting prosurvival Akt/NF-κB/mTOR signaling. J Exp Ther Oncol.
11:251–260. 2016.PubMed/NCBI
|
|
13
|
Shen YC, Kang CH and Chiang PH: Efficacy
of switching therapy of luteinizing hormone-releasing hormone
analogue for advanced prostate cancer. Kaohsiung J Med Sci.
32:567–571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsai YC, Chen WY, Siu MK, Tsai HY, Yin JJ,
Huang J and Liu YN: Epidermal growth factor receptor signaling
promotes metastatic prostate cancer through microRNA-96-mediated
downregulation of the tumor suppressor ETV6. Cancer Lett. 384:1–8.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Turkbey B, Mani H, Shah V, Rastinehad AR,
Bernardo M, Pohida T, Pang Y, Daar D, Benjamin C, McKinney YL, et
al: Multiparametric 3T prostate magnetic resonance imaging to
detect cancer: Histopathological correlation using prostatectomy
specimens processed in customized magnetic resonance imaging based
molds. J Urol. 186:1818–1824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bell N, Connor Gorber S, Shane A, Joffres
M, Singh H, Dickinson J, Shaw E, Dunfield L and Tonelli M; Canadian
Task Force on Preventive Health Care, : Recommendations on
screening for prostate cancer with the prostate-specific antigen
test. CMAJ. 186:1225–1234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Quan X, Lu S, Huang F, Yang J,
Chan Q and Lin T: The clinical value of dynamic contrast-enhanced
magnetic resonance imaging at 3.0T to detect prostate cancer. J Int
Med Res. 42:1077–1084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Frauscher F, Halpern EJ and Klauser A: Use
of MRI to detect lymph-node metastases in prostate cancer. N Engl J
Med. 349:1185–1186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eiber M, Holzapfel K, Ganter C, Epple K,
Metz S, Geinitz H, Kübler H, Gaa J, Rummeny EJ and Beer AJ:
Whole-body MRI including diffusion-weighted imaging (DWI) for
patients with recurring prostate cancer: Technical feasibility and
assessment of lesion conspicuity in DWI. J Magn Reson Imaging.
33:1160–1170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volkin D, Turkbey B, Hoang AN,
Rais-Bahrami S, Yerram N, Walton-Diaz A, Nix JW, Wood BJ, Choyke PL
and Pinto PA: Multiparametric magnetic resonance imaging (MRI) and
subsequent MRI/ultrasonography fusion-guided biopsy increase the
detection of anteriorly located prostate cancers. BJU Int.
114:E43–E49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanimoto A, Nakashima J, Kohno H, Shinmoto
H and Kuribayashi S: Prostate cancer screening: The clinical value
of diffusion-weighted imaging and dynamic MR imaging in combination
with T2-weighted imaging. J Magn Reson Imaging. 25:146–152. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anwar SS, Anwar Khan Z, Shoaib Hamid R,
Haroon F, Sayani R, Beg M and Khattak YJ: Assessment of apparent
diffusion coefficient values as predictor of aggressiveness in
peripheral zone prostate cancer: Comparison with Gleason score.
ISRN Radiol. 2014:2634172014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eschmann SM, Pfannenberg AC, Rieger A,
Aschoff P, Müller M, Paulsen F, Anastasiadis A, Claussen CD, Bares
R and Schlemmer HP: Comparison of 11C-choline-PET/CT and whole
body-MRI for staging of prostate cancer. Nuklearmedizin.
46:161–168; quiz N47-N48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Panebianco V, Sciarra A, Lisi D, Galati F,
Buonocore V, Catalano C, Gentile V, Laghi A and Passariello R:
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in
the detection of local prostate cancer recurrence in men with
biochemical progression after radical retropubic prostatectomy
(RRP). Eur J Radiol. 81:700–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
